CCXI News and Press, ChemoCentryx Inc. From 05/05/22

-- Five-fold increase in net sales of TAVNEOS ® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique P...

SAN CARLOS, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close on Thursday, May 5, 2022. ChemoCentryx executive management will host a conference call and ...

Pharmacodynamic results from a phase 1 trial demonstrated that ChemoCentryx's (CCXI) CCX559 exhibits immune stimulatory properties in cancer patients. CCX559 is an inhibitor of PD-L1 that is given in pill format. Currently available PD-L1 inhibitors are monoclonal antibodies that must be give...

-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic (PD) results show CCX559 exhibits immune stimulatory properties in cancer patients -- SAN CARLOS, Calif., April 13, 202...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Buying on the dip can be a risky strategy because you can't know when a stock has reached bottom until after it has recovered from it. The danger is always that a struggling stock can fall lower in the weeks and months ahead. However, by investing in stable businesses with attractive growth...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ChemoCentryx, Inc. (NasdaqGS: CCXI). On May 4, 2021, the U.S. Food and Drug Adminis...

The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: ChemoCentryx, Inc. 2021 Q4 - Results - Earnings Call Presentation

CCXI got its first approval last October. Revenue and patient uptake has been good. A few more quarters will be needed to assess the company properly. For further details see: ChemoCentryx: Good Post-Approval Performance, But Needs More Time